US20180028427A1 - Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations - Google Patents

Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations Download PDF

Info

Publication number
US20180028427A1
US20180028427A1 US15/722,448 US201715722448A US2018028427A1 US 20180028427 A1 US20180028427 A1 US 20180028427A1 US 201715722448 A US201715722448 A US 201715722448A US 2018028427 A1 US2018028427 A1 US 2018028427A1
Authority
US
United States
Prior art keywords
heparan sulfate
cosmetological
formulation
weight
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/722,448
Inventor
Luigi De Ambrosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratori Derivati Organici SpA
Original Assignee
Laboratori Derivati Organici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratori Derivati Organici SpA filed Critical Laboratori Derivati Organici SpA
Priority to US15/722,448 priority Critical patent/US20180028427A1/en
Publication of US20180028427A1 publication Critical patent/US20180028427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Definitions

  • the invention relates to a new process for the purification of heparan sulfate.
  • the present invention also relates to cosmetological and dermatological preparations making use of heparan sulfate.
  • Heparans are extracted from heparinoids which constitutes a by-product in the purification of heparin from pig intestinal mucosa. They are structural isomers formed during synthesis of glycosaminoglycanes (GAGS); highly sulfated and epimerised structures are typical of heparin, while highly epimerised and less N- and O-sulfated structures are typical of heparin-like structures presenting low anticoagulant activity.
  • GGS glycosaminoglycanes
  • the present invention relates to cosmetological and dermatological preparations comprising heparan sulfate, and their use as whitening, anti-wrinkle, lenitive and anti-oxidant agent. It has been surprisingly found that heparan sulfate is effective in the treatment of the above mentioned conditions.
  • the invention is directed to medical devices making use of heparan sulfate in the cosmetological and dermatological field.
  • the present invention is directed to a process for the purification of heparan sulfate, which process allows the use of pure heparan sulfate in dermatological and cosmetological applications.
  • the cosmetological and dermatological preparations according to the invention make use of purified heparan sulfate.
  • purification of heparan sulfate is an important step in order to remove residual compounds which are extracted with heparan sulfate but present different characteristics.
  • the purification process of the invention is characterized by the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin under conditions which result in selective desorption of heparan sulfate.
  • the anion exchange resin is preferably a strong base macroporous anion exchange resin such as, for example, LewatitTM S 6328 A.
  • the adsorption is performed by mixing a sufficient amount of resin beads.
  • the amount of beads is higher than 15 g of resin per gram of heparan sulfate, more preferably is comprised between 18 and 25 g resin per gram of heparan sulfate.
  • heparan sulfate is selectively desorbed by using an alkaline or alkaline earth metal salt, preferably an halogenide or an acetate.
  • suitable salts are magnesium dichloride, magnesium diacetate, sodium chloride, sodium acetate, potassium chloride and potassium acetate.
  • the pH of the salt solution is preferably comprised between 7.0 and 10.0.
  • the concentration of the salt is important in order to achieve complete and selective desorption of heparan sulfate. A preferred range of concentration is comprised between 0.3 M and 1.0 M, more preferably between 0.5 M and 0.8 M. In fact, if the concentration of the salt is too low, the desorption of heparan sulfate is incomplete. If the concentration is too high, the desorption is not selective and, together with heparan sulfate, also highly sulfated compounds are desorbed.
  • heparan sulfate is optionally further passed on a cationic resin and on a anionic resin.
  • a cationic resin is Amberlite Forte IR 120TM.
  • An example of a suitable cationic resin is Amberlite Forte IRA 410TM.
  • heparan sulfate Purified heparan sulfate according to the invention was tested in various dermatological and cosmetological applications. More specifically, heparan sulfate was tested for whitening, lenitive and anti-age effects. In all these applications heparan sulfate showed a significant activity.
  • a preferred embodiment of the present invention is directed to a cosmetological composition comprising heparan sulfate.
  • the cosmetological compositions according to the invention comprise from 0.01% by weight to 5% by weight of heparan sulfate, more preferably from 0.05% by weight to 2% by weight, even more preferably from 0.1% by weight to 1.0% by weight.
  • the molecular weight by weight (Mw) of the heparan sulfate suitable in the cosmetological and dermatological applications of the invention is preferably comprised between 6,000 and 12,000 Da.
  • cosmetological compositions according to the invention optionally comprise other substances such as preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, which are usually included in cosmetological and dermatological compositions.
  • compositions according to the present invention are used as anti-age product.
  • Many anti-age products often claim their ability to induce an increase in cell proliferation or in the protein synthesis on fibroblasts, with a linked improvement in cell firmness and thickness.
  • Fibroblasts are the main cell component in the connective tissue of the dermis and they are able to synthesize high amount of collagen and elastin, the main components of the dermis that play an essential role in the skin thickness and appearance.
  • the increase in protein amount for cell stimulates the ability of fibroblasts to synthesize collagen and elastin.
  • Oxidative stress is one of the main cause of aging process and is involved in the development of many serious human diseases. Exposure to UVA rays, pollutants, tobacco's smoke, as well as diet, drugs intake or pathologies can increase the level of oxidant activity in the skin cells or decrease the effectiveness of endogenous antioxidant systems. Following exposure to oxidative stress Reactive Oxygen Species (ROS) formation, damages to the cells membrane and to DNA may occur in the cell, leading to cell transformation or even death.
  • ROS oxidative stress Reactive Oxygen Species
  • compositions comprising heparan sulfate are effective both as anti-wrinkle compositions and as anti-oxidant compositions.
  • the resin was washed, transferred in a column (diameter 3 cm, length 40 cm) and eluted with a 5% by weight solution of MgCl 2 at pH 8.5.
  • the first 300 ml are collected, after which the solution did not show presence of heparan sulfate (negative reaction to quaternary ammonium).
  • the suspension is left at 15° C. for 12 h. Then the solid is collected, dissolved in 50 ml of water and precipitated by adding 100 nil of acetone.
  • Heparan sulfate is then dissolved in 100 ml of water and the solution is passed over a resin Amberlite Forte IR 120TM and then over a resin Amberlite Forte IRA 410 TM.
  • the eluate is neutralized by adding a 5% by weight solution of NaOH until pH 6.
  • Water is evaporated under vacuum, the solid is filtered on a 0.45 ⁇ m filter and lyophilised. Yield: 4.12 g.
  • the in vitro whitening effect of HS was detected by measurement of melanin content on melanoma cells B16 (fibroblast-like cells able to produce melanin) after 6 days of contact with HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).
  • NC negative control
  • PC positive control
  • HS heparan sulphate sodium salt
  • the test was performed in the single blind mode. 20 volunteers (age between 40-50 years) with aged spots where present (hand, forehead, arm, face, neck). The region with aged spots was divided in two zone: one for the treatment with tested substance, one with placebo. The spots were treated for 30 consecutive days: 1 application (1 mg of substance)/die on tested area (150-200 cm 2 ) [as per Colipa guideline].
  • the tested substance was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
  • Placebo was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
  • MI Melanin Index by Mexameter MX 18
  • Basophil cells when come in contact with irritant substances, give their biochemical response that is the secretion (by degranulation) of substances (such as histamine, leukotriens, proteolytic enzymes as hexosaminidase) that contribute to inflammatory events.
  • substances such as histamine, leukotriens, proteolytic enzymes as hexosaminidase
  • Inhibition in basophil cells degranulation is a measure of lenitive (anti-itching) effect of a substance.
  • the in vitro lenitive effect of HS was detected by measurement of the release of ⁇ -hexosaminidase after 2 h of contact with HS at 4 different concentrations: 10 mg/ml (1%), 5 mg/ml (0.5%), 1 mg/ml (0.1%), 0.2 mg/ml (0.02%).
  • the negative control was represented by untreated cells (cells without any substance).
  • the positive control was represented by basophil degranulation stimul (by crosslinking the receptor Fc ⁇ RI with a specific polyclonal antibody against to the ⁇ -chain stimulate the degranulation).
  • the maximal stimulation is: cell treated with 1% Triton X-100. The results are reported as Optical Density (OD) at 405 nm.
  • HS heparan sulphate sodium salt
  • ⁇ -hexosaminidase “natural” level, level without any contact with irritant substance is 0.054 (OD at 450 nm).
  • HS alone (at different concentration) has the same effect of negative control, that means leaves the cell with their “natural” level of ⁇ -hexosaminidase. This confirms that HS has no effect on basophil cells degranulation.
  • the test was performed in single blind mode. 20 volunteers (age between 36-52 years) were treated on a circumscribed treated zone of 1 cm 2 on the back of each volunteer: one for test substance application, one for placebo application, and one for control (untreated zone). The test was performed by a single application (2 mg of substance) on tested area (1 cm 2 ) [as per Colipa guideline]. Total time: 60 minutes after application
  • Tested substance was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
  • Placebo was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
  • the transient erythemagenic reaction is induced by exposure to a known amount of UVB radiation coming from a Solar Stimulator.
  • the evaluation (EI—Erythema Index by Mexameter MX 18) were made in the following way:
  • the antioxidant effect of HS is detected by measurement of reduction of free radicals as Reactive Oxygen Species (ROS) after exposure to 3 different UVA irradiation for 1 minute and 30 seconds (1′ 30′′), for 3 minutes (3′) and for 4 minutes and 30 seconds (4′ 30′′), with HS at 7 different concentrations: 0.031 mg/ml (0.0031%), 0.063 mg/ml (0.0063%), 0.125 mg/ml (0.0125%), 0.250 mg/ml (0.0250%), 0.500 mg/ml (0.0500%), 1.000 mg/ml (0.1000%) and 9.000 mg/ml (0.9000%).
  • the negative control (NC) was: untreated cells (cells without any substance).
  • the positive control (PC) was: Vitamin C (0.15 mg/ml) (0.015%).
  • Table VI shows the results obtained. It is evident that heparan sulphate sodium salt (HS) shows in vitro antioxidant effect.
  • HS heparan sulphate sodium salt
  • the efficacy of HS at 0.1% concentration is comparable or even higher than the efficacy of Vitamin C.
  • the efficacy of HS is higher that Vitamin C even at prolonged exposure to UVA radiation (4′ 30′′).
  • the mitogenic effect of HS is detected by measurement of fibroblast cells proliferation, measurement of protein synthesis after exposure for 48 hours and 72 hours, using HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).
  • the negative control (NC) is represented by untreated cells
  • the positive control (PC) is: EGF (Epidermal Growth Factor) (10 ⁇ g/ml) (0.001%).
  • heparan sulphate sodium salt shows in vitro cell proliferation and protein synthesis efficacy. The highest effect (18.2% for cell proliferation and 20.4% for protein synthesis) is observed after 72 hour from exposure at 0.05 mg/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin by using conditions which result in selective desorption of heparan sulfate. The cosmetological and dermatological compositions according to the invention show, inter alia, anti-age, lenitive, and whitening effect.

Description

  • The invention relates to a new process for the purification of heparan sulfate. The present invention also relates to cosmetological and dermatological preparations making use of heparan sulfate.
  • Heparans are extracted from heparinoids which constitutes a by-product in the purification of heparin from pig intestinal mucosa. They are structural isomers formed during synthesis of glycosaminoglycanes (GAGS); highly sulfated and epimerised structures are typical of heparin, while highly epimerised and less N- and O-sulfated structures are typical of heparin-like structures presenting low anticoagulant activity.
  • It is known that endogenous proteoglycans (PG) play an important role in wound healing (V. Prathiba and S. Gupta: Cutaneous wound healing: Significance of proteoglycans in scar formation”. Current Science, vol. 78, no 6, 2000). However, the prior art does not describe the effect of administration of proteoglycans and, more specifically, of heparan sulfate in cosmetological and dermatological applications.
  • The present invention relates to cosmetological and dermatological preparations comprising heparan sulfate, and their use as whitening, anti-wrinkle, lenitive and anti-oxidant agent. It has been surprisingly found that heparan sulfate is effective in the treatment of the above mentioned conditions.
  • In a further embodiment, the invention is directed to medical devices making use of heparan sulfate in the cosmetological and dermatological field.
  • In another preferred embodiment, the present invention is directed to a process for the purification of heparan sulfate, which process allows the use of pure heparan sulfate in dermatological and cosmetological applications.
  • In a preferred embodiment, the cosmetological and dermatological preparations according to the invention make use of purified heparan sulfate. In fact, purification of heparan sulfate is an important step in order to remove residual compounds which are extracted with heparan sulfate but present different characteristics.
  • The purification process of the invention is characterized by the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin under conditions which result in selective desorption of heparan sulfate.
  • The anion exchange resin is preferably a strong base macroporous anion exchange resin such as, for example, Lewatit™ S 6328 A. The adsorption is performed by mixing a sufficient amount of resin beads. Preferably the amount of beads is higher than 15 g of resin per gram of heparan sulfate, more preferably is comprised between 18 and 25 g resin per gram of heparan sulfate.
  • After adsorption on the anion exchange resin, heparan sulfate is selectively desorbed by using an alkaline or alkaline earth metal salt, preferably an halogenide or an acetate. Examples of suitable salts are magnesium dichloride, magnesium diacetate, sodium chloride, sodium acetate, potassium chloride and potassium acetate. The pH of the salt solution is preferably comprised between 7.0 and 10.0. The concentration of the salt is important in order to achieve complete and selective desorption of heparan sulfate. A preferred range of concentration is comprised between 0.3 M and 1.0 M, more preferably between 0.5 M and 0.8 M. In fact, if the concentration of the salt is too low, the desorption of heparan sulfate is incomplete. If the concentration is too high, the desorption is not selective and, together with heparan sulfate, also highly sulfated compounds are desorbed.
  • After desorption from the anion exchange resin, heparan sulfate is optionally further passed on a cationic resin and on a anionic resin. An example of suitable anionic resin is Amberlite Forte IR 120™. An example of a suitable cationic resin is Amberlite Forte IRA 410™.
  • Purified heparan sulfate according to the invention was tested in various dermatological and cosmetological applications. More specifically, heparan sulfate was tested for whitening, lenitive and anti-age effects. In all these applications heparan sulfate showed a significant activity.
  • A preferred embodiment of the present invention is directed to a cosmetological composition comprising heparan sulfate.
  • Preferably, the cosmetological compositions according to the invention comprise from 0.01% by weight to 5% by weight of heparan sulfate, more preferably from 0.05% by weight to 2% by weight, even more preferably from 0.1% by weight to 1.0% by weight.
  • The molecular weight by weight (Mw) of the heparan sulfate suitable in the cosmetological and dermatological applications of the invention is preferably comprised between 6,000 and 12,000 Da.
  • The cosmetological compositions according to the invention optionally comprise other substances such as preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, which are usually included in cosmetological and dermatological compositions.
  • In a preferred embodiment, the compositions according to the present invention are used as anti-age product. Many anti-age products often claim their ability to induce an increase in cell proliferation or in the protein synthesis on fibroblasts, with a linked improvement in cell firmness and thickness.
  • Fibroblasts are the main cell component in the connective tissue of the dermis and they are able to synthesize high amount of collagen and elastin, the main components of the dermis that play an essential role in the skin thickness and appearance. The increase in protein amount for cell stimulates the ability of fibroblasts to synthesize collagen and elastin.
  • Another claim for anti-aging and protective cosmetics is their activity in counteracting oxidative stress and free-radicals release in the skin. Oxidative stress is one of the main cause of aging process and is involved in the development of many serious human diseases. Exposure to UVA rays, pollutants, tobacco's smoke, as well as diet, drugs intake or pathologies can increase the level of oxidant activity in the skin cells or decrease the effectiveness of endogenous antioxidant systems. Following exposure to oxidative stress Reactive Oxygen Species (ROS) formation, damages to the cells membrane and to DNA may occur in the cell, leading to cell transformation or even death.
  • The induction of fibroblasts proliferation and protein synthesis in dermis cells are of great concern for actives targeted to anti-age topical products.
  • It has been found that compositions comprising heparan sulfate are effective both as anti-wrinkle compositions and as anti-oxidant compositions.
  • EXPERIMENTAL
  • Organic sulfur, Uronic acid, Glucosamine, Optical rotation, total nitrogen and APTT were measured in accordance with the European Pharmacopeia, 4th edition. Electrophoresis was performed in accordance with R. Cappelletti et al. “A new Electrophoretic method for the separation of all Gags” Anal. Biochem. 99:311-315 (1979).
  • Molecular mass (Mw) was determined by size exclusion chromatography (European Pharmacopoeia 4th ed.: 2.2.30 and 2.2.46 for chromatography techniques and 01/2002:0828 p. 1297 for method).
  • Purification of Heparan Sulfate
  • 5 g of heparan sulfate from pig intestinal mucosa were dissolved in 200 ml of demineralised water. 90 g of Lewatit S 6238 A™ were added to the solution. The mixture was slowly stirred at room temperature for 72 h and then filtered. The filtrate was analysed and no heparan sulfate was detected.
  • The resin was washed, transferred in a column (diameter 3 cm, length 40 cm) and eluted with a 5% by weight solution of MgCl2 at pH 8.5.
  • The first 300 ml are collected, after which the solution did not show presence of heparan sulfate (negative reaction to quaternary ammonium).
  • The solution is brought to pH=6 with a 10% solution of hydrochloric acid and heparan sulfate is precipitated by adding 600 ml of acetone. The suspension is left at 15° C. for 12 h. Then the solid is collected, dissolved in 50 ml of water and precipitated by adding 100 nil of acetone.
  • Heparan sulfate is then dissolved in 100 ml of water and the solution is passed over a resin Amberlite Forte IR 120™ and then over a resin Amberlite Forte IRA 410 ™. The eluate is neutralized by adding a 5% by weight solution of NaOH until pH 6. Water is evaporated under vacuum, the solid is filtered on a 0.45 μm filter and lyophilised. Yield: 4.12 g.
  • Analysis: Rotation=+50.62°. Organic S=9.07%. Uronic acid=31.97%. Glucosamine=37%. Total N=2.26%. AP i=6.31 U/mg. Mw=7538 Da (Before purification 8729 Da).
  • Test for Whitening Efficacy Evaluation In Vitro Evaluation of the Bleaching Activity of a Raw Material on Cell Cultures—Test Procedure
  • The in vitro whitening effect of HS was detected by measurement of melanin content on melanoma cells B16 (fibroblast-like cells able to produce melanin) after 6 days of contact with HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%).
  • The negative control (NC) was represented by untreated cells (cell without any substance). The positive control (PC) was represented by cells treated with Hydroquinone 5 μg/ml (0.0005%). On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro whitening effect.
  • TABLE I
    Melanin Content
    (μg melanin/mg % Melanin Synthesis
    protein) Inhibition vs NC
    HS (0.01%) 41.9 10.3
    HS (0.005%) 44.4 5.2
    PC: Hydroquinone (0.0005%) 10.8 76.8
    NC: untreated cells 46.8
  • In Vivo—Whitening Efficacy Evaluation of a Cosmetic Formulation on 20 Volunteers Test Procedure:
  • The test was performed in the single blind mode. 20 volunteers (age between 40-50 years) with aged spots where present (hand, forehead, arm, face, neck). The region with aged spots was divided in two zone: one for the treatment with tested substance, one with placebo. The spots were treated for 30 consecutive days: 1 application (1 mg of substance)/die on tested area (150-200 cm2) [as per Colipa guideline].
  • The tested substance was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
  • Placebo was an emulsion of the following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium EDTA.
  • The evaluation (MI—Melanin Index by Mexameter MX 18) was made in the following way:
      • T0—basal value, value of Melanin Index before the application of substance.
      • T15—value of Melanin Index after 15 days of substance application.
      • T30—final value, value of Melanin Index at the end of test (after 30 days of substance application).
  • TABLE II
    T0 MI ± std dev T15 MI ± std dev T30 MT ± std dev
    HS 0.9% 229.09 ± 44.06 222.00 ± 58.37 220.81 ± 54.25
    Placebo 199.89 ± 55.89 205.84 ± 55.95 215.07 ± 75.45
  • The decrease of MI (Melanin Index) in the area treated with tested substance, versus MI treated with placebo, after 30 days of application, resulted statistically relevant (p<0.01). Hence the Whitening Effect of tested substance (emulsion with 0.9% Heparan Sulphate sodium salt) was confirmed.
  • Test for Lenitive Efficacy Evaluation
  • In Vitro—Degranulation Test on Basophil Cells with Cosmetic Raw Materials—Test Procedure
  • Basophil cells, when come in contact with irritant substances, give their biochemical response that is the secretion (by degranulation) of substances (such as histamine, leukotriens, proteolytic enzymes as hexosaminidase) that contribute to inflammatory events.
  • Inhibition in basophil cells degranulation is a measure of lenitive (anti-itching) effect of a substance. The in vitro lenitive effect of HS was detected by measurement of the release of β-hexosaminidase after 2 h of contact with HS at 4 different concentrations: 10 mg/ml (1%), 5 mg/ml (0.5%), 1 mg/ml (0.1%), 0.2 mg/ml (0.02%).
  • The negative control (NC) was represented by untreated cells (cells without any substance). The positive control (PC) was represented by basophil degranulation stimul (by crosslinking the receptor FcεRI with a specific polyclonal antibody against to the α-chain stimulate the degranulation). The maximal stimulation (degranulation) is: cell treated with 1% Triton X-100. The results are reported as Optical Density (OD) at 405 nm.
  • TABLE III
    release of β-hexosaminidase
    OD at 450 nm
    NC: untreated cells 0.054
    PC: basophil degranulation 0.117
    Max Stimulation 0.377
    HS 10 mg/ml 0.066
    HS 5 mg/ml 0.059
    HS 1 mg/ml 0.062
    HS 0.2 mg/ml 0.061
    HS 10 mg/ml + PC 0.061
    HS 5 mg/ml + PC 0.055
    HS 1 mg/ml + PC 0.110
    HS 0.2 mg/ml + PC 0.112
  • On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro lenitive effect.
  • The β-hexosaminidase “natural” level, level without any contact with irritant substance is 0.054 (OD at 450 nm). HS alone (at different concentration) has the same effect of negative control, that means leaves the cell with their “natural” level of β-hexosaminidase. This confirms that HS has no effect on basophil cells degranulation.
  • When the cells come in contact with an irritant substance (positive control) the value increase at 0.117, or higher to 0.377 when in contact with Triton X-100 (1%).
  • When the cells come in contact both with an irritant substance (positive control) and HS the level of β-hexosaminidase decrease in a dose dependent way, with best efficacy with HS at 0.5% and 1%, hence HS has a lenitive (anti-itching) effect.
  • In Vivo—Lenitive Efficacy Evaluation on a Cosmetic Formulation on 20 Volunteers—Short Term Test—Test Procedure
  • The test was performed in single blind mode. 20 volunteers (age between 36-52 years) were treated on a circumscribed treated zone of 1 cm2 on the back of each volunteer: one for test substance application, one for placebo application, and one for control (untreated zone). The test was performed by a single application (2 mg of substance) on tested area (1 cm2) [as per Colipa guideline]. Total time: 60 minutes after application
  • Tested substance was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, 0.9% heparan sulfate sodium salt, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
  • Placebo was an emulsion of following composition: aqua, ethylhexyl palmitate, cetearyl alcohol, carbomer, acrylates/c-10-30 alkyl acrylate crosspolymer, sodium hydroxide, phenoxyethanol, propylene glycol, methylparaben, ethylparaben, propylparaben, disodium edta.
  • The transient erythemagenic reaction is induced by exposure to a known amount of UVB radiation coming from a Solar Stimulator. The evaluation (EI—Erythema Index by Mexameter MX 18) were made in the following way:
      • T0—basal value, value of Erythema Index after UVB radiation and before the application of substance
      • T15—value of Erythema Index after 15 minutes from substance application
      • T30—value of Erythema Index after 30 minutes from substance application
      • T60—value of Erythema Index after 60 minutes from substance application
  • TABLE IV
    T0 EI ± std T15 EI ± std T30 EI ± std T60 EI ± std
    dev dev dev dev
    Tested Substance 455.75 ± 64.63 439.55 ± 82.67 421.59 ± 72.31 406.39 ± 77.06
    Placebo 453.21 ± 71.50 430.26 ± 76.22 415.69 ± 67.42 415.79 ± 75.18
  • TABLE V
    T0 vs T15 T0 vs T30 T0 vs T60
    Tested Substance −4.19 −8.29 −11.24
    Placebo −5.36 −8.29 −8.58
  • The decrease of EI (Erythema Index) in the area treated with tested substance, versus EI treated with placebo, after 60 minutes from application, resulted statistically relevant (p<0.1), and is statistically relevant (p<0.01) the decrease after 60 minutes versus basal value. Hence the Lenitive (redness reduction) Effect of tested substance (emulsion with 0.9% Heparan Sulphate sodium salt) has been confirmed.
  • Test for Anti-Wrinkle Efficacy Evaluation
  • In vitro Evaluation of the anti-ageing activity of cosmetic products through the investigation of their anti-oxidant and protective activity against UVA on human keratinocytes cell cultures.
  • Test Procedure
  • The antioxidant effect of HS is detected by measurement of reduction of free radicals as Reactive Oxygen Species (ROS) after exposure to 3 different UVA irradiation for 1 minute and 30 seconds (1′ 30″), for 3 minutes (3′) and for 4 minutes and 30 seconds (4′ 30″), with HS at 7 different concentrations: 0.031 mg/ml (0.0031%), 0.063 mg/ml (0.0063%), 0.125 mg/ml (0.0125%), 0.250 mg/ml (0.0250%), 0.500 mg/ml (0.0500%), 1.000 mg/ml (0.1000%) and 9.000 mg/ml (0.9000%). The negative control (NC) was: untreated cells (cells without any substance). The positive control (PC) was: Vitamin C (0.15 mg/ml) (0.015%).
  • Table VI shows the results obtained. It is evident that heparan sulphate sodium salt (HS) shows in vitro antioxidant effect. The efficacy of HS at 0.1% concentration is comparable or even higher than the efficacy of Vitamin C. The efficacy of HS is higher that Vitamin C even at prolonged exposure to UVA radiation (4′ 30″).
  • TABLE VI
    Heparan Sulphate Sodium Salt Vit C
    mg/ml mg/ml
    Exposure 9.000 1.000 0.500 0.250 0.125 0.063 0.031 0.15
    ROS Inhibition 1′30″ UVA 30.7 38.7 30.6 28.0 23.5 25.4 25.3 33.5
    % 3′00″ UVA 31.6 35.7 29.1 22.9 14.2 21.8 20.1 31.4
    4′30″ UVA 26.3 30.4 24.7 18.1 10.3 13.7 6.2 12.7
  • In Vitro—Mitogenic Activity Evaluation of a Raw Material Test Procedure:
  • The mitogenic effect of HS is detected by measurement of fibroblast cells proliferation, measurement of protein synthesis after exposure for 48 hours and 72 hours, using HS at 2 different concentrations: 0.1 mg/ml (0.01%) and 0.05 mg/ml (0.005%). The negative control (NC) is represented by untreated cells, the positive control (PC) is: EGF (Epidermal Growth Factor) (10 μg/ml) (0.001%).
  • TABLE VII
    % cell proliferation vs NC
    48 h 72 h
    PC: EGF (10 μg/ml) (0.001%) 112.5 121.6
    HS 0.1 mg/ml (0.01%) 110.5 118.1
    HS 0.05 mg/ml (0.005%) 106.7 118.2
    % protein synthesis vs NC
    48 h 72 h
    PC: EGF (10 μg (0.001%) 116.6 119.0
    HS 0.1 mg/ml (0.01%) 103.1 113.2
    HS 0.05 mg/ml (0.005%) 110.2 120.4
  • On the basis of results obtained, heparan sulphate sodium salt (HS) shows in vitro cell proliferation and protein synthesis efficacy. The highest effect (18.2% for cell proliferation and 20.4% for protein synthesis) is observed after 72 hour from exposure at 0.05 mg/ml.

Claims (14)

1-13. (canceled)
14. A method of reducing itching, the method comprising applying a formulation comprising heparan sulfate to a patient in need thereof.
15. The method of claim 14, wherein the formulation comprises from 0.01 to 5% by weight heparan sulfate.
16. The method of claim 14, wherein the formulation comprises from 0.05 to 2% by weight heparan sulfate.
17. The method of claim 14, wherein the formulation comprises from 0.1 to 1% by weight heparan sulfate.
18. The method of claim 14, wherein the heparan sulfate has a molecular weight between 6,000 and 12,000 Da.
19. The method of claim 14, wherein the formulation further comprises one or more of the following ingredients: preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, and other components which are included in cosmetological and dermatological formulations.
20. The method of claim 14, wherein the formulation is an emulsion.
21. A method for reducing free radicals as Reactive Oxygen Species (ROS) and increasing cell proliferation and protein synthesis, the method comprising applying a formulation comprising heparan sulfate to a patient in need thereof.
22. The method of claim 21, wherein the formulation comprises from 0.01 to 5% by weight heparan sulfate.
23. The method of claim 21, wherein the formulation comprises from 0.05 to 2% by weight heparan sulfate.
24. The method of claim 21, wherein the formulation comprises from 0.1 to 1% by weight heparan sulfate.
25. The method of claim 21, wherein the heparan sulfate has a molecular weight between 6,000 and 12,000 Da.
26. The method of claim 21, wherein the formulation further comprises one or more of the following ingredients: preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, and other components which are included in cosmetological and dermatological formulations.
US15/722,448 2008-11-20 2017-10-02 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations Abandoned US20180028427A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/722,448 US20180028427A1 (en) 2008-11-20 2017-10-02 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP08169547 2008-11-20
EP08169547.0 2008-11-20
PCT/EP2009/062582 WO2010057710A2 (en) 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US13/129,030 US9440099B2 (en) 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US15/228,150 US20160338935A1 (en) 2008-11-20 2016-08-04 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US15/722,448 US20180028427A1 (en) 2008-11-20 2017-10-02 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/228,150 Division US20160338935A1 (en) 2008-11-20 2016-08-04 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Publications (1)

Publication Number Publication Date
US20180028427A1 true US20180028427A1 (en) 2018-02-01

Family

ID=41587870

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/129,030 Active 2031-03-25 US9440099B2 (en) 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US15/228,150 Abandoned US20160338935A1 (en) 2008-11-20 2016-08-04 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US15/722,448 Abandoned US20180028427A1 (en) 2008-11-20 2017-10-02 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/129,030 Active 2031-03-25 US9440099B2 (en) 2008-11-20 2009-09-29 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
US15/228,150 Abandoned US20160338935A1 (en) 2008-11-20 2016-08-04 Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations

Country Status (14)

Country Link
US (3) US9440099B2 (en)
EP (2) EP2679278B1 (en)
JP (3) JP2012509289A (en)
KR (1) KR101669528B1 (en)
DK (2) DK2679278T3 (en)
ES (2) ES2650937T3 (en)
HR (2) HRP20140862T1 (en)
HU (1) HUE035362T2 (en)
LT (1) LT2679278T (en)
NO (1) NO2679278T3 (en)
PL (2) PL2346573T3 (en)
PT (2) PT2679278T (en)
SI (2) SI2346573T1 (en)
WO (1) WO2010057710A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2679278T3 (en) * 2008-11-20 2018-02-03
FR3000067B1 (en) * 2012-12-21 2016-05-13 Oreal C-XYLOSIDE COMPOUNDS, COMPOSITIONS AND THEIR USE FOR DEPIGMENTING THE SKIN
JP6321786B2 (en) 2013-05-16 2018-05-09 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Heparan sulfate
US10493012B2 (en) 2014-11-19 2019-12-03 Agency For Science, Technology And Research Cosmetic use of heparan sulphate
SG11201704085QA (en) 2014-11-19 2017-06-29 Agency Science Tech & Res Heparan sulphates for use in repair and/or regeneration of skin
ITUB20160156A1 (en) * 2016-02-05 2017-08-05 Laboratori Derivati Organici Spa COMPOSITIONS INCLUDING A MIXTURE OF GLYCOSAMINOGLICANS AND THEIR USE IN COSMETIC AND DERMATOLOGICAL COMPOSITIONS
CN108329405B (en) * 2018-02-08 2020-06-23 黄石市典雅生物科技有限公司 Method for protecting and purifying heparin sodium in resin adsorption state
CN111909288B (en) * 2020-08-13 2021-09-03 山东辰龙药业有限公司 Refining method of heparin sodium
KR20220096932A (en) 2020-12-31 2022-07-07 주식회사 유연테크 Dehumidifying cyclone dryer that combines dust removal and dehumidification
WO2024072942A2 (en) * 2022-09-29 2024-04-04 Adora Animal Health Corporation Skin penetrating formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150209A (en) * 1986-12-15 1988-06-22 Kanebo Ltd Skin cosmetic
IT1212143B (en) * 1987-06-26 1989-11-08 Crinos Industria Farmaco COMPOSITION WITH TRICHOGENIC ACTIVITY.
JPH0696514B2 (en) * 1987-07-15 1994-11-30 鐘紡株式会社 Skin cosmetics
JPH06104620B2 (en) * 1987-07-15 1994-12-21 鐘紡株式会社 Skin cosmetics
DK505488D0 (en) * 1987-12-21 1988-09-09 Bar Shalom Daniel MEDIUM AND USE OF SAME
FR2643909B1 (en) * 1989-03-03 1993-01-22 Bioetica Sa BASIC COMPOSITION FOR THE PREPARATION OF A COSMETIC COMPOSITION FORMING A HAIR COMPOSITION AND COSMETIC COMPOSITION FORMING A HAIR COMPOSITION THUS PREPARED, CONTAINING HEPARIN OR HEPARANE SULPHATE
JPH03161416A (en) * 1989-11-21 1991-07-11 Kanebo Ltd Skin cosmetic
JP2931083B2 (en) * 1990-11-22 1999-08-09 ポーラ化成工業株式会社 Skin cosmetics
JPH05310548A (en) * 1992-05-13 1993-11-22 Taisho Pharmaceut Co Ltd Skin external preparation
GB9318288D0 (en) * 1993-09-03 1993-10-20 Nycomed Imaging As Improvements in or relating to contrast agents
SE9402531L (en) 1994-07-19 1996-01-20 Medicarb Ab wound healing agent
JPH0899861A (en) * 1994-09-30 1996-04-16 Kose Corp Skin external agent
US5989874A (en) * 1995-03-27 1999-11-23 Tayca Corporation Humectant, antistatic agent, dispersant and film-forming agent having polysaccharide as active principle, preparation process of polysaccharides, and Kliebsiella ocytoca TNM-3 strain
US6537977B1 (en) * 1995-09-19 2003-03-25 Seikagaku Corporation Anti-inflammatory agent
JP3687277B2 (en) * 1997-06-10 2005-08-24 サンスター株式会社 Whitening cosmetics
GB9913237D0 (en) * 1999-06-08 1999-08-04 K C L Enterprises Limited Product
JP4754066B2 (en) * 2000-12-22 2011-08-24 株式会社林原生物化学研究所 Anti-joint disorder
JP2003171256A (en) * 2001-12-03 2003-06-17 Nonogawa Shoji Kk Skin care preparation
DE10161149B4 (en) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Use of heparin-containing ophthalmic agent
US20070129430A1 (en) * 2003-10-07 2007-06-07 Satomi Miyata Agent for enhancing the production of collagen, their preparation and use
DE102004036689A1 (en) * 2004-07-28 2006-03-23 Henkel Kgaa Low-residue deodorant or antiperspirant stick based on an oil-in-water dispersion
JP4975751B2 (en) * 2005-10-13 2012-07-11 グ、ジェニファー、エル. Minerals, collagens and chelates and their production and use
JP2007254316A (en) * 2006-03-22 2007-10-04 Seikagaku Kogyo Co Ltd Hyaluronic acid (ha) matrix formation inhibitor
JP4564471B2 (en) * 2006-07-06 2010-10-20 株式会社コーセー Composition suitable for external use
ITMI20072237A1 (en) * 2007-11-27 2009-05-28 Sigea Srl MIXED BUTIRRIC-FORMAL ESTERS OF ACID POLYSACCHARIDES, THEIR PREPARATION AND USE AS DERMOCOSMETICS
NO2679278T3 (en) * 2008-11-20 2018-02-03

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H03161416 JP A *

Also Published As

Publication number Publication date
DK2679278T3 (en) 2017-12-11
ES2650937T3 (en) 2018-01-23
DK2346573T3 (en) 2014-10-06
KR101669528B1 (en) 2016-10-26
EP2679278A1 (en) 2014-01-01
WO2010057710A9 (en) 2011-08-18
HUE035362T2 (en) 2018-05-02
ES2507495T3 (en) 2014-10-15
PL2346573T3 (en) 2014-12-31
PT2346573E (en) 2014-09-25
JP2014159488A (en) 2014-09-04
SI2346573T1 (en) 2014-10-30
HRP20171861T1 (en) 2018-01-26
NO2679278T3 (en) 2018-02-03
EP2346573A2 (en) 2011-07-27
SI2679278T1 (en) 2018-02-28
JP2012509289A (en) 2012-04-19
WO2010057710A2 (en) 2010-05-27
JP6058588B2 (en) 2017-01-11
KR20110086734A (en) 2011-07-29
LT2679278T (en) 2017-12-27
WO2010057710A3 (en) 2011-06-03
US20160338935A1 (en) 2016-11-24
EP2679278B1 (en) 2017-09-06
JP2017043638A (en) 2017-03-02
US9440099B2 (en) 2016-09-13
PT2679278T (en) 2017-12-13
PL2679278T3 (en) 2018-02-28
US20110288047A1 (en) 2011-11-24
EP2346573B1 (en) 2014-06-25
HRP20140862T1 (en) 2014-11-07

Similar Documents

Publication Publication Date Title
US9440099B2 (en) Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations
JP2014159488A5 (en)
KR100755798B1 (en) A topical composition comprising extracts of feverfew tanacetum parthenium and method of treating and preventing inflammatory disorders using the composition
EP1049451B1 (en) Use of compounds for protecting skin from uv induced immunosuppression
EP1863430B1 (en) Composition based on vegetal extracts of ajuga reptans for preventing hair loss, stimulating the growth of hair, regulating the production of sebum.
CA2703532C (en) Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
KR101436199B1 (en) Composition for Improving Skin Conditions Comprising Hordenine
US20070167517A1 (en) Stabilized derivatives of ascorbic aicd
US20120245120A1 (en) Zinc sucrose octasulfates, their preparation, and pharmaceutical and cosmetic uses thereof
KR20140012456A (en) Composition for improving skin conditions comprising akebia saponin d
KR20160024527A (en) Skin agent composition containing Rumex obtusifolius extract
KR20070096279A (en) A cosmetic composition comprising rumex crispus l. extracts
Haxaire et al. Effect of L‐4‐Thiazolylalanine (Protinol™) on skin barrier strength and skin protection
KR101460672B1 (en) Composition for preventing hair damage containing the extract of mycoleptodonoides aitchisonii fruit body
JP3120086B2 (en) Hair cosmetics for prevention of gray hair and blackening of gray hair
JPH05221834A (en) Hair cosmetic for preventing gray hair and blackening gray hair
WO2024120853A1 (en) Compositions comprising sanguisorba officinalis root extract and uses thereof
KR101460670B1 (en) Acne preventing and treating composition containing the extract of mycoleptodonoides aitchisonii fruit body
KR100986128B1 (en) A skin-care agent containing Coniogramme japonica extract
JPH02268192A (en) Retinoic acid ester of d-desosamine, its production, medicine for human or veterinary use and cosmetic composite
JPH06256144A (en) Hair cosmetic for preventing white hair and blacking white hair
KR20160025112A (en) Skin agent composition containing Rumex obtusifolius extract
WO2007064966A2 (en) Pharmaceutical and dermatocosmetic compositions comprising extract of durio zibethinus

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION